Nektar Therapeutics Cash and Restricted Cash
Nektar Therapeutics (NKTR) had Cash and Restricted Cash of $39.27 million as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-14
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $39.27M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $149.58M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $15.12M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $41.03M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2026-06-30 | $39.27M 10-Q · filed 2026-08-14 |
| 2026-03-31 | $149.58M 10-Q · filed 2026-05-08 |
| 2025-12-31 | $15.12M 10-Q · filed 2026-08-14 |
| 2025-09-30 | $41.03M 10-Q · filed 2025-11-07 |
| 2025-06-30 | $42.99M 10-Q · filed 2026-08-14 |
| 2025-03-31 | $38.89M 10-Q · filed 2026-05-08 |
| 2024-12-31 | $44.25M 10-Q · filed 2026-08-14 |
| 2024-09-30 | $30.11M 10-Q · filed 2025-11-07 |
| 2024-06-30 | $27.94M 10-Q · filed 2025-08-08 |
| 2024-03-31 | $48.64M 10-Q · filed 2025-05-09 |
| 2023-12-31 | $35.28M 10-K · filed 2026-03-13 |
| 2023-09-30 | $64.92M 10-Q · filed 2024-11-08 |
| 2023-06-30 | $50.73M 10-Q · filed 2024-08-09 |
| 2023-03-31 | $76.95M 10-Q · filed 2024-05-10 |
| 2022-12-31 | $88.23M 10-K · filed 2025-03-14 |
| 2022-09-30 | $105.76M 10-Q · filed 2023-11-08 |
| 2022-06-30 | $77.55M 10-Q · filed 2023-08-09 |
| 2022-03-31 | $67.99M 10-Q · filed 2023-05-10 |
| 2021-12-31 | $25.22M 10-K · filed 2024-03-05 |
| 2021-09-30 | $54.02M 10-Q · filed 2022-11-04 |
| 2021-06-30 | $152.34M 10-Q · filed 2022-08-05 |
| 2021-03-31 | $150.16M 10-Q · filed 2022-05-06 |
| 2020-12-31 | $198.96M 10-K · filed 2024-03-05 |
| 2020-09-30 | $55.84M 10-Q · filed 2021-11-05 |
| 2020-06-30 | $58.21M 10-Q · filed 2021-08-06 |
| 2020-03-31 | $227.03M 10-Q · filed 2021-05-07 |
| 2019-12-31 | $96.36M 10-K · filed 2023-02-28 |
| 2019-09-30 | $81.22M 10-Q · filed 2020-11-06 |
| 2019-06-30 | $85.42M 10-Q · filed 2020-08-07 |
| 2019-03-31 | $106.75M 10-Q · filed 2020-05-08 |
| 2018-12-31 | $194.91M 10-K · filed 2022-03-01 |
| 2018-09-30 | $222.26M 10-Q · filed 2019-11-07 |
| 2018-06-30 | $911.13M 10-Q · filed 2019-08-09 |
| 2017-12-31 | $4.76M 10-K · filed 2021-02-26 |
| 2016-12-31 | $59.64M 10-K · filed 2020-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |